



Oslo Cancer Cluster

11

RESULTS FROM 2011



ANNUAL REPORT 2011 > FROM CANCER RESEARCH TO CURE



Norwegian
Centres of Expertise

.....
COLOPHON:

Editor and text: Elisabeth Kirkeng Andersen, Oslo Cancer Cluster

Photo credit: Linda Cartridge, Oslo University Hospital, DiaGenic, Sverre Chr. Jarild,
Dark Architects, ECCP2011, Elisabeth Kirkeng Andersen & Epitarget.

Design and layout: Fete Typer

Production: RK grafisk

Print run: 500

Published: May 2012
.....

CONTENTS

Page 4: Oslo Cancer Cluster in short

Page 6: The Board of Oslo Cancer Cluster

Page 8: From the Chairman of the Board

11 RESULTS FROM 2011:

Page 10: ① National Platform for Stratified Medicine

Page 12: ② 14 New Members

Page 14: ③ Highlights Oslo Cancer Cluster Members

Page 16: ④ Public Policy

Page 18: ⑤ Communication is Core

Page 20: ⑥ Clinical Trials Efficiency

Page 22: ⑦ Oslo Cancer Cluster Innovation Park

Page 24: ⑧ Educating Tomorrow`s Researchers and Entrepreneurs

Page 26: ⑨ Vital Networking Arena`s with Record Interest

Page 28: ⑩ Record Attendance at ECCP2011

Page 30: ⑪ Oslo Cancer Cluster Made an Impact at BIO 2011

DEDICATED ONCOLOGY CLUSTER

Oslo Cancer Cluster is an oncology research and industry cluster organized as a non-profit member organization. We are dedicated to accelerating the development of new cancer diagnostics and medicines.



Oslo Cancer Cluster was established in 2006, and has nearly 70 members from Norway, as well as Northern Europe. In June 2007, the cluster became a Norwegian Centre of Expertise (NCE).

Our members represent the entire oncology value chain from bench to bedside, and comprise small biotechnology companies, large pharmaceutical companies, university hospitals, biobanks and registries, patient organisations, technology transfer offices and academic research institutions.

OUR STRATEGY: We will accelerate the development of new cancer diagnostics and medicines through concentrating our work on the following six strategic areas:

1. COLLABORATIVE NETWORKS AND PARTNERING

Oslo Cancer Cluster will stimulate collaboration and partnerships by further develop national and international networks.

2. INNOVATION

Oslo Cancer Cluster will stimulate and support innovations and start-up activities.

3. ACCESS TO CAPITAL

Oslo Cancer Cluster shall strengthen its members' ability to attract capital and the conditions for attracting capital for its members.

4. CLINICAL TRIALS EFFICIENCY

Oslo Cancer Cluster shall contribute to improved clinical trial efficiency for its members.

5. PUBLIC POLICY

Oslo Cancer Cluster shall strengthen governmental focus and improve public policies for the cancer community.

6. WORKFORCE DEVELOPMENT

Oslo Cancer Cluster will engage in developing and attracting top talents to cancer R&D and entrepreneurship.

OUR VISION: “We are committed to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.”



THE BOARD OF OSLO CANCER CLUSTER

The Board of Oslo Cancer Cluster is made up of nine skilled and competent board members who reflect the oncology value chain from research to large pharmaceutical companies.

CHAIRMAN OF THE BOARD:



Jónas Einarsson CEO of the Radium Hospital Research Foundation

Jónas Einarsson, M.D, is the CEO of The Radium Hospital Research Foundation, that is an experienced pre-seed investor and project developer who focuses on oncology. Einarsson is on the board of several Norwegian biotech companies, and was one of the initiators behind the Oslo Cancer Cluster in 2006. He has been the Chairman of the Board since then.

BOARD MEMBERS:



Henrik Lund Chairman Board of Directors, DiaGenic ASA

Henrik Lund holds a MD PhD from the University of Oslo. Mr. Lund has 15 years of experience from the pharmaceutical industry, with 10 years of experience from AstraZeneca and 5 years heading up the AstraZenecas Clinical Development organization in their global marketing organization. Lund serves as Chairman Board of Directors in DiaGenic ASA.



Tone Ikdahl Head of Department, Cancer Clinic, Oslo University Hospital, Ullevål

Tone Ikdahl's background is that of a molecular genetics scientist with particular focus on breast cancer at Professor Anne-Lise Børresen –Dales lab. Currently Ikdahl is focusing on translational and clinical research on several cancer forms, such as pancreas cancer and colon cancer. She is now Head of the Department at the Cancer Clinic at the Oslo University Hospital, Ullevål.



Bjørn Klem Project Director, Photocure ASA

Bjørn Klem holds a Master of Science in Pharmacy from the University of Oslo. In Photocure, Mr. Klem has been in charge of exploratory projects including clinical development of both Metvix® and Hexvix®, which have both successfully been introduced to markets world-wide. Currently he is in charge of a new project for treatment of HPV infection and cervical pre-cancer.



Håkon Sæterøy Managing Director, Investor Corporate AS

Håkon Sæterøy has more than 20 years' experience in the investment industry and corporate finance – the last ten years mainly in the life sciences sector. He is Chairman of the Board of Nansen Neuroscience Network and Epitarget AS and board member of Skannex AS. He holds an MSc from the Norwegian School of Economics and Business Administration.



Ragnhild Lothe Professor, Oslo University Hospital, Radium

Professor Lothe is the Head of Department of Cancer Prevention at the Norwegian Radium Hospital and professor at the Department of Molecular Bio-Sciences at the University of Oslo. She is also the vice-director of the Centre for Cancer Biomedicine that is a Norwegian Centre of Excellence.



Hanne Mette D. Kristensen CEO, Targovax AS

Hanne Mette D. Kristensen is the CEO of Targovax AS. She has a strong track record in commercialization of research and early phase company development, and holds a M.Sc. in biochemistry from the University of Oslo, and an MBA in Technology Management (MTM) from NTNU, NHH and MIT Sloan School of Management.



Rolf Bjerkvig Professor, University of Bergen

Dr. Bjerkvig is professor of Cell Biology at the University of Bergen, Norway and is also Head of the Oncology Department, Centre Recherche Public de la Santé in Luxembourg. He is on the editorial board of several international journals and is on several national as well as international funding committees for cancer in Europe.



Gunn Christophersen Business Unit Director, Roche Norway

Gunn Christophersen is Business Unit Director at Roche Norway. She has more than 30 years' experience in the pharmaceutical industry, mainly within the field of oncology treatment.



Kaare Norum Professor Emeritus, University of Oslo

Kaare Norum is an honorary member of Oslo Cancer Cluster, and was one of the initiators of the cluster in 2006. He was Vice Chairman of the Board from 2006, and is very active in the ongoing establishment of Oslo Cancer Cluster Innovation Park.



From the Chairman of the Board:

Major opportunities & Main challenges

Oslo Cancer Cluster is continuously expanding both in terms of new members, activities and results. In fall 2011 we worked hard on our new strategy that was completed at the start of 2012.

“The strategy sets the direction for our work in the years to come until the Innovation Park is up and running in 2014. I am confident that through our strategic areas, we will be able to accelerate the development of new cancer treatments, which is our vision,” says Jónas Einarsson, Chairman of the Board of Oslo Cancer Cluster and CEO of the Radium Hospital Research Foundation.

Mr. Einarsson points out two crucial incidents during 2011 that represent major opportunities in order to solve the main challenges the oncology sector in Norway now faces: To maintain and increase the number of clinical trials in Norway, as well as attracting capital and fostering innovation.

“First of all, the Norwegian Government launched a new strategy for the biotech area for the next 9 years. I am pleased to see that the focus on both health and commercialisation is in line with our recommendations. We have high expectations of Biotek 2021: the new Biotech for Innovation programme,” says Einarsson.

Einarsson also has great belief in the Oslo Cancer Cluster’s initiative “National Platform for Stratified Medicine” that was formally launched at Cancer Crosslinks 2012.

“This national platform’s overall aim is to ensure that patients receive fast and accurate diagnoses and access to the right treatment at the right time. The platform will also make Norway a more attractive place for clinical trials within oncology. This is crucial for Norwegian cancer patients, as well as the oncology sector as a whole,” says Einarsson.

11

RESULTS FROM 2011



1

National Platform for Stratified

Norway initiates a national pilot platform using whole genome sequencing to optimize treatment decision and cancer care.

Developing a National Platform for Stratified Medicine is certainly one of the most relevant results of 2011 and will positively affect the future development of the Oslo Cancer Cluster.

The increasing number of targeted cancer drugs triggers the need for refined diagnostics approaches. With reference to the British Stratified Medicine Initiative run by Cancer Research UK, Pfizer Norway's Oncology Business started a Norwegian initiative in collaboration with the Oslo Cancer Cluster. With involvement of all member groups, the project developed throughout the year, and was officially launched at the Oslo Cancer Cluster signature meeting Cancer Crosslinks in January 2012, featuring a round-table conference with James Peach, Director for the Stratified Medicine Initiative.

This project is crucial for maintaining the high quality of cancer R&D in Norway, and was already featured in a

Nature news article because of its innovative character. The aim of the program is to build a national diagnostics platform based on next generation sequencing. This will ensure that every cancer diagnosis triggers molecular testing to identify the right treatment for the individual patient. During the initial pilot phase, 4000 tumour/blood sample pairs for several tumour types will be sequenced to identify relevant mutations and to better understand treatment responses.

The implementation of this personalized medicine platform in conjunction with the comprehensive Norwegian Cancer Registry should also be an attractive offer for pharmaceutical companies looking for high quality clinical trial partners.

More information is available on <http://cancergenomics.no>

Medicine



2

14 New Members

Oslo Cancer Cluster expanded its organisation with the inclusion of 14 new members in 2011. We are especially glad to announce that 2011 was the year when the Bergen-environment joined forces with us, with the addition of the University of Bergen, Haukeland University Hospital, as well as the tech transfer office BTO (Bergen Teknologioverføring).

We now have nearly 70 members from Norway as well as Northern Europe.

Research:

Centre for Cancer Biomedicine –
A Norwegian Centre for Excellence
www.cancerbiomed.net
University of Bergen
www.uib.no/en/

Recruitment and workforce:

Kelly Scientific Resources
[www.kellyservices.no/NO/
Tjenester/
Life-Science-og-legemiddelindustrien](http://www.kellyservices.no/NO/Tjenester/Life-Science-og-legemiddelindustrien)

University Hospital:

Haukeland University Hospital
www.helse-bergen.no/english

Law firm:

Grette
www.grette.no

CRO:
SMS Oncology
www.sms-oncology.com

Tech transfer:
BTO (Bergen Teknologioverføring)
<http://bergento.no>

Biotech start-ups:
Ultimovacs
www.ultimovacs.com
Targovax
www.targovax.com
Oncoinvent
www.oncoinvent.com
Apim Therapeutics
www.apimtherapeutics.com

Specialty Logistics:
World Courier
www.worldcourier.com

**Biotechnology products
and service:**
Life Technologies
www.lifetechnologies.com

Pharma:
Mundipharma
www.mundipharma.no



Name: Thora Jonasdottir
Position: CEO, Oncoinvent

Why did Oncoinvent decide to join the Oslo Cancer Cluster?

“Because we believe that a biotechnology company in its infancy, such as Oncoinvent AS, has so many benefits from a membership in Oslo Cancer Cluster, such as being updated by news and events, and networking through participation in R&D meetings, conferences and parties. To discuss and learn, and possibly establish collaboration with the other members, is very valuable in the early phases.”

3

Highlights Oslo Cancer Clusters

Algeta´s big breakthrough

In June 2011 Algeta announced that their global phase III clinical trial of the use of Alpharadin® to treat prostate cancer that has spread to the bone, met its primary endpoint as an interim analysis showed that Alpharadin® prolongs patients survival time while offering a well tolerated safety profile.

In August 2011, Alpharadin® was granted Fast Track Designation by the FDA.

www.algeta.com

Innovation Prizes to PCI Biotech

PCI Biotech won two prizes in DNB NORs Innovation Prize Award 2011.

As well as receiving most votes in the “People´s Choice Award” among ten nominees, they also won the main prize of NOK 1 MIO among 716 companies.

www.pcibiotech.no

Targovax raises \$ 1,6 MIO

Targovax AS receives \$ 1,6 MIO (NOK 9 MIO) in support from the Innovation Norway OFU-programme to develop a therapeutic cancer vaccine targeting operated pancreatic cancer.

www.targovax.com

LINK in Denmark

LINK Medical Research opened a new office in Copenhagen. Their strategy is to continue to strengthen their position as a provider of clinical trials and regulatory services in Scandinavia.

<http://linkmedical.no>

Good examples

The new national biotech strategy for 2011–2020 will focus on both health and commercialization, and mentions Oslo Cancer Cluster and member companies like Photocure, Algeta, DiaGenic, Clavis Pharma and PCI Biotech as good examples within the sector.

www.regjeringen.no/upload/KD/Vedlegg/Kompetanse/bioteknologistrategi.pdf

Bjørn Rune Gjelsten on board in Ultimovacs

The cancer vaccine company Ultimovacs was established in 2011. None other than Bjørn Rune Gjelsten is one of the main investors along with the Radium Hospital Research Foundation and Inven2.

www.ultimovacs.com

CCB: "Exceptionally good"

The Centre for Cancer Biomedicine, a Norwegian Centre of Excellence, was in an international evaluation, ranked as "Exceptionally Good": "CCB delivers at a very high level," states the evaluation and points out the societal impact of their research in the form of better cancer patient care.

www.med.uio.no/ccb/english

Algeta, PCI and Clavis succeeded with public funding

The Norwegian Research Council (NRC) granted Algeta, PCI Biotech and Clavis support to their R&D projects through the NRC-programme "User-driven Research-based Innovation". The competition for funding was its fiercest ever according to the Research Council.

www.algeta.com

www.pcibiotech.com

www.clavispharma.com

11 ongoing clinical trials

Roche has 11 ongoing clinical trials within oncology in Norway in 2011. The clinical trials are within the following disease areas; breast cancer, lymphoma, colorectal cancer, malignant melanoma and ovarian cancer.

www.roche.no

Record grant from the Cancer Society

The Norwegian Cancer Society is the largest non-government sponsor of independent cancer research in the country. In 2011 they granted \$ 32 MIO (186 MIO) to cancer research in Norway.

This is a new all time high.

www.kreftforeningen.no/english

Epitarget is a Eurostar

Epitarget and their French partners EDAP TMS and INSERM gained a EUR 1.1 MIO grant from the European Union Eurostars programme to accelerate the transfer of the consortium's ultrasound triggered drug delivery technology from laboratory to patient.

www.epitarget.com

4 Public Policy

Oslo Cancer Cluster works hard to increase the governmental focus and framework conditions for the biotech sector.

In 2011 the Norwegian Government launched a new strategy for the biotech area for the next 9 years. Both the focus on health and commercialisation is in line with our proposals for the strategy. We have high expectations of Biotek 2021: the Biotech for Innovation Programme in the Norwegian Research Council that will be the manifestation of the strategy in practice.

Hopefully the members of Oslo Cancer Cluster will successfully gain grants from the Biotech Innovation Programme. We will do our best to help them succeed.

The National Budget for 2012 is, overall, “biotech friendly,” as the government recognizes biotechnology as an important sector for growth and industry in the budget.

We are pleased that Investinor, a government-funded investment company, is strengthened with an additional 1, 5 billion NOK to make investments in early phase companies in the budget.

In Spring 2012 the government announced that Investinor will increase their investment activity in the biotech/health sector.

The government also proposes in the budget to fund R&D intensive industry and commercialization of research with NOK 2, 2 billion.

This includes increased R&D funds for biotech and nanotech. This is also in line with our thoughts, but we would in addition like to see a governmental seed capital fund for biotech helping the start-up companies to succeed during the challenging first years.



“

HEALTH RELATED BIOTECHNOLOGY INDUSTRY

Health is a dominant field within biotechnological R&D, innovation and business development in Norway. Several companies have been successful in later years. Photocure, Algeta, DiaGenic, Clavis Pharma and PCI Biotech are at the head of a growing cluster of biotechnology companies on the Oslo Stock Exchange. Both Photocure and Diagenic have been able to take their commercialisation all the way to products on the market. Photocure, Algeta and Clavis have signed large, international contracts which have drawn much attention. A large number of companies of this type show that the health related biotechnology industry has had a positive development. Most of the companies are situated in the Oslo region.”

Quote from National Strategy for Biotechnology 2011–2020
– For the value creation, health and environment of the future,
The Ministry of Education and Research

5

Communication is Core

The Oslo Cancer Cluster has since the start in 2006 focused on communication, branding and profiling. In 2011 we strengthened our organisation by hiring one full time communication employee dedicated to this task.

Oslo Cancer Cluster communicates through several media channels. Most important is our webpage oslocancercluster.no, which in 2011 had 14.000 unique guests whom visited 29.000 times.

Marketing and communication is an important part of the work we do when attending international conferences and events. We make sure to promote the attending members; connecting them with media covering the conferences. In 2011 this included international conferences such as BIO, EPIC and ECCP as well as national conferences such as Cancer Crosslinks and Onkologisk Fagdag.

Oslo Cancer Cluster makes one annual supplement distributed by Aftenposten each October during the Pink Ribbon Month: "Kampen mot Kreft". In 2011 we performed an audience measurement for the first time, and the feedback was positive. We use the supplement to focus on causes we work for, as well as to inform about oncology R&D projects our members are involved in.

In 2011 we had a special focus on Social Medias, building up groups and relations on Facebook, Twitter and LinkedIn.

MEDIA COVERAGE:

(Estimated by digital surveillance only)

Oslo Cancer Cluster

National media coverage in Norway: 63 articles

Member companies*

National media coverage in Norway: 2731 articles

International media coverage: 13.232 articles

*SMEs involved in cancer research and development

KAMPEN MOT KREFT
Andre utgave om norsk kreftforskning og -utvikling


Nanotek og ultralyd
gir gode resultater
side 6


Bjørn bidrar til ny
behandling
side 4

Bjørn Rune Gjelsten
Investerte i norsk kreftvaksine da faren ble syk
side 10-11

Ultern skole i unik forskningspark. Side 12

Forskere i Bergen fikk milliongaver. Side 14

Norske sykehus henger etter. Danske kirurger ser kreftsvulster med norsk blålys. Side 12

Veiviser i helseinvesteringer
Birk Venture –
Les mer på side 7



SOCIAL MEDIAS:

 Oslo Cancer Cluster- group: 2.202 fans

 557 followers of @elikirand and 254 followers of @SusanWer

 165 members of the closed Oslo Cancer Cluster group

6

Clinical Trials Efficiency

Oslo Cancer Cluster has since 2006 worked with clinical trials efficiency. To maintain a high level of clinical trials within oncology, it is important to secure the patients' access to new and innovative cancer treatments.

In Norway, oncology clinical trials are mainly performed at Oslo University Hospital and Haukeland University Hospital in Bergen.

➤ Oslo Cancer Cluster has worked closely with the Clinical Cancer Research Unit at Oslo University Hospital (OUS) for several years. This is one of Scandinavia's leading facilities in the field of early phase clinical trials. Together with the Radium Hospital Research Foundation, we have strengthened the capacity at the Unit with an annual grant for an oncologist position. Oslo Cancer Cluster also helped facilitate new collaborations between the unit and Sanofi, Bayer and Toulouse University Hospital in 2011.
Read more on: <http://www.ous-research.no/cru/>

➤ 2011 saw the birth of the Nordic Network for Early Clinical Trials (Nordic Nect). Nordic Nect is a cooperation between phase I units in Denmark, Finland, Norway and Sweden, performing early clinical trials in oncology. Professor

Steinar Aamdal from the Clinical Cancer Research Unit at OUS, is heading the network.
Read more on: www.nordicnect.org

➤ In 2011 Haukeland University Hospital, Bergen joined the Oslo Cancer Cluster. Haukeland has a young and ambitious clinical trials unit, also including paediatrics named Helse Bergen Clinical Research Unit. Last year the unit performed 14 clinical trials, six within oncology including one academic phase I study. The unit's strategy is to focus more on cancer and early clinical trials within the Oslo Cancer Cluster.
Read more on: www.haukeland.no/english/Sider/side.aspx

The last years have shown a decrease in the number of clinical trials performed by international pharma companies in Norway, a situation we take very seriously and therefore address in our work.



7

Oslo Cancer Cluster Innovation



The Oslo Cancer Cluster Innovation Park will foster innovations within oncology as well as integrating Ullern High School. Illustration: Dark Architects.

Park

Oslo Cancer Cluster Innovation Park has been a dream for the oncology environment in the Oslo-area for a long time. The fundamental idea behind the Innovation Park is to gather the whole oncology community in Oslo together at Montebello, where the renowned Oslo University Hospital, Radium, has been located since 1932.

There is a broad political support for the Innovation Park in Oslo, and politicians have praised the concept behind the park and the added values the Innovation Park will provide the city of Oslo.

The Oslo Cancer Cluster Innovation Park will be built on a total of 32,000 m², housing the Cancer Registry of Norway, several of the members of the Oslo Cancer Cluster and both the Oncology Pathology Lab and Institute for Medical Informatics at Oslo University Hospital, as well as Ullern High School.

Oslo Cancer Cluster will in collaboration with the Radium Hospital Research Foundation set up an oncology biotech incubator in the Innovation Park in order to facilitate oncology start-ups and speed up both innovation and help young companies making it.

The Innovation Park will open in August 2014.

8

Educating tomorrow's researchers

The development and attraction of top talents within cancer R&D and entrepreneurship is an area Oslo Cancer Cluster focuses on. In 2011 we worked on three different projects relating to this.



Master students at Centre for Entrepreneurship, University of Oslo presenting their exam project on Oslo Cancer Cluster 2012.

and entrepreneurs

Researcher Anette Weyergang at the Institute for Cancer Research, OUS, helps out the students from Ullern High School doing their internship.

OSLO CANCER CLUSTER + ULLERN = THE TRUTH

Oslo Cancer Cluster and Ullern High School collaborate closely to educate tomorrow's researchers and entrepreneurs by the concept "The School of the Future." This collaboration is due to the future integration of the Ullern High School within the Oslo Cancer Cluster Innovation Park.

2011 was the second year the biology students had mini-internships at the Oslo University Hospital, Radium to gain practical experience. 16 students worked in real laboratories on real research questions, supervised by real researchers. Also we continued our lecture series given by researchers and member companies for the students. In total 5 lectures were organised. More activities will be developed for the students in the years to come.

BIOACCELERATOR

In collaboration with Centre for Entrepreneurship at University of Oslo, the Oslo Cancer Cluster organizes a Bio-Accelerator each year. This is an internship for the students at the Centre for Entrepreneurship in which they are given the opportunity to solve business problems for member companies of Oslo Cancer Cluster.

In 2011, Oslo Cancer Cluster had 2 interns from Toulouse help us with an overview of innovation parks internationally, mapping their strong and weak sides as important contribution for developing the concept for the cancer focused innovation park in Oslo.



WIN – WIN COMMUNICATION SCHEME

Teachers from Ullern High School and adjacent primary schools "educated" PhDs in medicine on how to communicate in a new PhD course. The course is a collaboration project between Ullern, Oslo Cancer Cluster and the Medical Faculty at the University of Oslo. 13 PhD students were selected for the course and held a 20 minute presentation on their PhD project, whilst they then received feedback on their communication skills from the teachers. The teachers received valuable and updated knowledge on the medical research forefront that they could then use in the classroom.

9

Vital Networking Arena's with

Building strong national and international networks in order to stimulate collaboration and partnerships is vital.

In 2011, Oslo Cancer Cluster organized five R&D Networking Meetings with record attendance, reflecting the increased involvement and interest from the Norwegian Oncology community. In addition, our signature meeting Cancer Crosslinks, sponsored by BMS and MSD, was fully booked, with around 200 attendees, and has established itself as a crucial meeting place for oncologists, clinicians and researchers.

 ONKOLOGISK
F A G D A G

Onkologisk Fagdag was launched as a new event in 2011 on the members initiative. Onkologisk Fagdag presents the latest news from ASCO® and targets Norwegian clinicians and researchers within oncology that are refrained from going to the actual meeting in the US.

Onkologisk Fagdag featured lectures on lessons from ASCO® for an audience of over 50 clinicians and researchers from all over Norway. The seminar received great feedback. 97% stated they would like to attend next year's meeting. Onkologisk Fagdag was arranged in collaboration with the Norwegian Association of Clinical Oncology (Norsk onkologisk forening), and was sponsored by Amgen, Pfizer and Clavis Pharma.

Onkologisk Fagdag takes place June 13th 2012.

Record Interest

OSLO CANCER CLUSTER HOSTED MEETINGS 2011:

Time	Name of Event	Attendees
January	Cancer Crosslinks 2011, sponsored by BMS and MSD	200
March	R&D Network Meeting on “Personalized Medicine”	69
May	R&D Network Meeting on “Clinical Trials”	60
June	Onkologisk Fagdag, arranged in collaboration with the Norwegian Association of Clinical Oncology, and sponsored by Amgen, Pfizer and Clavis Pharma.	50
August	R&D Network Meeting featuring the “New Kids on the Block” + Summer Party	150
September	European Cancer Cluster Partnering Event 2011, Toulouse, France	445
October	R&D Network Meeting on “Drug Delivery & Nanoparticles”, organised in collaboration with SINTEF	56
December	Christmas R&D Network Meeting + Christmas party	89

INTERNATIONAL AND NATIONAL CONFERENCES OSLO CANCER CLUSTER ATTENDED:

May:	The Nordic-German-Polish Cluster Excellence Conference, Copenhagen, Denmark
June:	EPIC Biotech, London, UK – Gold Sponsor – 5 member companies presenting and 2 more present
June:	BIO, Washington D.C, USA – 15 member companies present
November:	BIO-Europe 2011 in Düsseldorf, Germany
November:	Onkologisk Forum, Oslo, Norway

10

ECCP2011 with Record

➤ 445 participants ➤ 285 companies ➤ 19 countries ➤ 1800 contacts generated

ECCP has been successfully established as an annual partnering arena for the international oncology community. The 3rd event in 2011 held in Toulouse, France gathered a record number of 445 participants from 285 companies and organizations from 19 countries. 1800 formal and informal contacts were reported and almost 40% of the participants estimated two agreements as result of their attendance.

An Oncology-focused Technology Showcase with close to 100 companies was organized in collaboration with Medicon Valley Alliance to further strengthen the value proposition of ECCP. 97% of the participants were very satisfied or satisfied with the program and enjoyed excellent networking. 89% stated they were planning to attend ECCP2012.

Eleven companies and institutions from the Oslo Cancer Cluster participated. Among them, Affitech presented

during the Technology Showcase, whilst BerGenBio and PCI Biotech gave company presentations in the main programme. Clinicians from the clinical trials unit at Oslo University Hospital used ECCP to meet their counterparts from Toulouse University Hospital, which has resulted in collaboration within the field of lung cancer. In addition they had successful partnering meetings with representatives from international pharmaceutical companies.

ECCP is a joint venture between the Oslo Cancer Cluster and its partner, the French Cancer Bio- Santé cluster from Toulouse.

Save the date
for **ECCP2012** in a new,
compact format,
November 11th 2012
in **Hamburg**,
as a satellite event
preceding BIO-Europe.

Attendance



Jónas Einarsson, Chairman of the Board of Oslo Cancer Cluster giving his opening speech at ECCP2011. Pierre Montoriol, Chairman of the Board, Cancer Bio- Santé and Dr. Judy Britz, Executive Director, Maryland Biotechnology Center to the right.



11

BIO2011: Oslo Cancer Cluster

BIO International Convention is the largest annual event for the global biotech industry, and the 2011 edition took place in Washington DC. Oslo Cancer Cluster attended for the 5th time with 15 companies. In total, 24 companies participated from Norway.

The Oslo Cancer Cluster exhibited in the Scandinavian Pavilion and featured the following members at the stand; Affitech, Epitarget, Photocure, Lytix Biopharma, Clavis Pharma, PCI Biotech, Targovax, BerGenBio, Bio-Medisinsk Innovasjon, Inven2, Skannex, Norwegian Institute of Public Health and Nexus Oncology. All companies were active in the partnering events during the conference.

For the 4th year, Oslo Cancer Cluster and the French oncology cluster Cancer-Bio-Santé, organized a partnering breakfast during BIO. Companies from both clusters presented themselves to major pharmaceutical companies and international investors.

BIO 2011 was a successful event for the attending companies; it extended their international contacts and business partnerships, and they were able to establish relevant new contacts with related international oncology environments.


Oslo Cancer Cluster will also attend BIO 2012 in Boston with several member companies. This year we will organise an International Cancer Cluster Showcase. Massachusetts, Quebec, Toulouse, Oslo and the UK “golden triangle” have teamed up to present our innovative oncology pipelines to an international oncology community at the Whitehead Institute.

Read more on www.mattcenter.org/cancercluster/home.html



BIO 2012
Please come visit us at the
Scandinavian
Pavilion, booth nr. 3055.

made an impact



Name: Esben Nilssen
Position: CEO, Epitarget

What does it mean for Epitarget that Oslo Cancer Cluster facilitates for your company to go to BIO?

Oslo Cancer Cluster improves the renom  and visibility of Norwegian biotechs at the BIO Conference.



Members by April 2012

www.oslocancercluster.no

